Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 326; no. 1; pp. 209 - 217
• Main Authors: Fell, Matthew J., Svensson, Kjell A., Johnson, Bryan G., Schoepp, Darryle D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2008; American Society for Pharmacology and Experimental Therapeutics
• Subjects: Animals; Antipsychotic Agents - pharmacology; Bridged Bicyclo Compounds, Heterocyclic - pharmacology; Cyclic S-Oxides - pharmacology; Drug Evaluation, Preclinical - methods; Excitatory Amino Acid Agonists - pharmacology; Female; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Motor Activity - drug effects; Motor Activity - physiology; Receptors, Metabotropic Glutamate - agonists; Receptors, Metabotropic Glutamate - physiology

(–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) is a potent and selective group II metabotropic glutamate [(mGlu)2 and mGlu3] receptor agonist for which its prodrug LY2140023 [(1 R,4 S,5 S,6 S)-2-thiabicyclo[3.1.0]-hexane-4,6-dicarboxylic acid,4-[(2 S)-...